Regencell Bioscience [RGC] vs Haleon Plc - ADR [HLN] Detailed Stock Comparison
Regencell Bioscience
NASDAQ
Loading...
Haleon Plc - ADR
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Regencell Bioscience wins in 4 metrics, Haleon Plc - ADR wins in 10 metrics, with 0 ties. Haleon Plc - ADR appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Regencell Bioscience | Haleon Plc - ADR | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -1,779.13 | 19.93 | Regencell Bioscience |
| Price-to-Book Ratio | 1,121.43 | 5.08 | Haleon Plc - ADR |
| Debt-to-Equity Ratio | 0.00 | 53.41 | Regencell Bioscience |
| PEG Ratio | N/A | 21.36 | N/A |
| EV/EBITDA | -1,913.48 | 33.86 | Regencell Bioscience |
| Profit Margin (TTM) | 0.00% | 13.81% | Haleon Plc - ADR |
| Operating Margin (TTM) | 0.00% | 22.21% | Haleon Plc - ADR |
| EBITDA Margin (TTM) | N/A | 22.21% | N/A |
| Return on Equity | -47.77% | 9.38% | Haleon Plc - ADR |
| Return on Assets (TTM) | -30.65% | 4.61% | Haleon Plc - ADR |
| Free Cash Flow (TTM) | $-4.01M | $2.67B | Haleon Plc - ADR |
| Dividend Yield | N/A | 1.63% | N/A |
| 1-Year Return | 14,581.82% | -14.37% | Regencell Bioscience |
| Price-to-Sales Ratio (TTM) | N/A | 3.63 | N/A |
| Enterprise Value | $7.64B | $119.46B | Haleon Plc - ADR |
| EV/Revenue Ratio | N/A | 8.07 | N/A |
| Gross Profit Margin (TTM) | N/A | 55.38% | N/A |
| Revenue per Share (TTM) | $0 | $2 | Haleon Plc - ADR |
| Earnings per Share (Diluted) | $-0.01 | $0.45 | Haleon Plc - ADR |
| Beta (Stock Volatility) | 2.15 | 0.24 | Haleon Plc - ADR |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Regencell Bioscience vs Haleon Plc - ADR Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Regencell Bioscience | 2.02% | 6.67% | 25.68% | 55.89% | 2,504.84% | 12,323.08% |
| Haleon Plc - ADR | -1.44% | 1.83% | -9.02% | -13.45% | -12.60% | -5.93% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Regencell Bioscience | 14,581.82% | 1,845.78% | 5,667.86% | 5,667.86% | 5,667.86% | 5,667.86% |
| Haleon Plc - ADR | -14.37% | 45.81% | 19.84% | 19.84% | 19.84% | 19.84% |
News Based Sentiment: Regencell Bioscience vs Haleon Plc - ADR
Regencell Bioscience
News based Sentiment: POSITIVE
The month of October 2025 showed positive movement in investor sentiment with a decrease in short interest and a higher-than-average news sentiment score. However, the lack of insider and institutional activity tempers the overall outlook, suggesting a need for continued monitoring.
Haleon Plc - ADR
News sentiment data is not available for Haleon Plc - ADR at this time.
Performance & Financial Health Analysis: Regencell Bioscience vs Haleon Plc - ADR
| Metric | RGC | HLN |
|---|---|---|
| Market Information | ||
| Market Cap | $7.64B | $41.72B |
| Market Cap Category | Mid cap | Large cap |
| 10 Day Avg. Volume | 183,082 | 9,529,570 |
| 90 Day Avg. Volume | 247,494 | 8,844,817 |
| Last Close | $16.15 | $8.88 |
| 52 Week Range | $0.09 - $83.60 | $8.71 - $11.42 |
| % from 52W High | -80.68% | -22.24% |
| All-Time High | $950.00 (May 30, 2025) | $11.42 (Jun 02, 2025) |
| % from All-Time High | -98.30% | -22.24% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | -0.01% |
| Quarterly Earnings Growth | N/A | 0.33% |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | 0.14% |
| Operating Margin (TTM) | 0.00% | 0.22% |
| Return on Equity (TTM) | -0.48% | 0.09% |
| Debt to Equity (MRQ) | 0.00 | 53.41 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $0.01 | $1.77 |
| Cash per Share (MRQ) | N/A | $0.08 |
| Operating Cash Flow (TTM) | $-3,881,392 | $3.34B |
| Levered Free Cash Flow (TTM) | $-4,301,837 | $2.58B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.63% |
| Last 12-Month Dividend | N/A | $0.17 |
Valuation & Enterprise Metrics Analysis: Regencell Bioscience vs Haleon Plc - ADR
| Metric | RGC | HLN |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -1,779.13 | 19.93 |
| Forward P/E | N/A | 21.36 |
| PEG Ratio | N/A | 21.36 |
| Price to Sales (TTM) | N/A | 3.63 |
| Price to Book (MRQ) | 1,121.43 | 5.08 |
| Market Capitalization | ||
| Market Capitalization | $7.64B | $41.72B |
| Enterprise Value | $7.64B | $119.46B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | N/A | 8.07 |
| Enterprise to EBITDA | -1,913.48 | 33.86 |
| Risk & Other Metrics | ||
| Beta | 2.15 | 0.24 |
| Book Value per Share (MRQ) | $0.01 | $1.77 |
Financial Statements Comparison: Regencell Bioscience vs Haleon Plc - ADR
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | RGC | HLN |
|---|---|---|
| Revenue/Sales | N/A | $3.72B |
| Cost of Goods Sold | N/A | $1.66B |
| Gross Profit | N/A | $2.06B |
| Research & Development | N/A | $105.17M |
| Operating Income (EBIT) | N/A | $471.91M |
| EBITDA | N/A | $488.09M |
| Pre-Tax Income | N/A | $388.31M |
| Income Tax | N/A | $88.99M |
| Net Income (Profit) | N/A | $299.32M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | RGC | HLN |
|---|---|---|
| Cash & Equivalents | $2.96M | $911.46M |
| Total Current Assets | $8.11M | $5.59B |
| Total Current Liabilities | $193,578 | $6.42B |
| Long-Term Debt | $25,934 | $10.30B |
| Total Shareholders Equity | $8.22M | $21.57B |
| Retained Earnings | $-21.62M | $36.76B |
| Property, Plant & Equipment | $84,780 | $2.52B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | RGC | HLN |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | RGC | HLN |
|---|---|---|
| Shares Short | 1.68M | 15.71M |
| Short Ratio | 6.07 | 1.93 |
| Short % of Float | 0.02% | 0.00% |
| Average Daily Volume (10 Day) | 183,082 | 9,529,570 |
| Average Daily Volume (90 Day) | 247,494 | 8,844,817 |
| Shares Outstanding | 494.49M | 12.25B |
| Float Shares | 18.43M | 8.99B |
| % Held by Insiders | 0.96% | 0.00% |
| % Held by Institutions | 0.00% | 0.13% |
Dividend Analysis & Yield Comparison: Regencell Bioscience vs Haleon Plc - ADR
| Metric | RGC | HLN |
|---|---|---|
| Last 12-Month Dividend | N/A | $0.17 |
| Last 12-Month Dividend Yield | N/A | 1.63% |
| 3-Year Avg Annual Dividend | N/A | $0.11 |
| 3-Year Avg Dividend Yield | N/A | 0.91% |
| 3-Year Total Dividends | N/A | $0.34 |
| Ex-Dividend Date | N/A | Apr 25, 2025 |